ImmuneOncia Therapeutics, Inc. Logo

ImmuneOncia Therapeutics, Inc.

A biopharma firm developing immune checkpoint inhibitors for cancer immunotherapy.

424870 | KO

Overview

Corporate Details

ISIN(s):
KR7424870004
LEI:
Country:
South Korea
Address:
경기도 용인시 기흥구 탑실로35번길 25, 용인시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ImmuneOncia Therapeutics, Inc. is a clinical-stage, immuno-oncology-centric biopharmaceutical company dedicated to developing cutting-edge immunotherapies for cancer treatment. Established in 2016 as a joint venture between Yuhan Corporation and Sorrento Therapeutics, the company leverages expertise in drug development and antibody engineering. ImmuneOncia's pipeline focuses on developing immune checkpoint inhibitors targeting T cells and macrophages. Its portfolio includes IMC-001, its lead candidate, and IMC-002, a fully human anti-CD47 monoclonal antibody for various cancers.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 887.8 KB
2025-05-30 00:00
Share Issue/Capital Change
주식매수선택권행사
Korean 43.9 KB
2025-05-23 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 102.9 KB
2025-05-23 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-05-12 00:00
Share Issue/Capital Change
증권발행실적보고서
Korean 323.5 KB
2025-04-30 00:00
Registration Form
[발행조건확정]증권신고서(지분증권)
Korean 525.5 KB
2025-04-30 00:00
Prospectus
[기재정정]투자설명서
Korean 3.9 MB
2025-04-28 00:00
Prospectus
투자설명서
Korean 3.3 MB
2025-04-18 00:00
Registration Form
[기재정정]증권신고서(지분증권)
Korean 3.4 MB
2025-04-17 00:00
Registration Form
[기재정정]증권신고서(지분증권)
Korean 4.2 MB
2025-04-04 00:00
Registration Form
[기재정정]증권신고서(지분증권)
Korean 3.9 MB
2025-04-02 00:00
Registration Form
[기재정정]증권신고서(지분증권)
Korean 3.5 MB
2025-03-28 00:00
Annual / Quarterly Financial Statement
감사보고서 (2024.12)
Korean 397.2 KB
2025-03-14 00:00
Registration Form
증권신고서(지분증권)
Korean 3.1 MB
2024-04-08 00:00
Annual / Quarterly Financial Statement
감사보고서 (2023.12)
Korean 355.7 KB

Automate Your Workflow. Get a real-time feed of all ImmuneOncia Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ImmuneOncia Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ImmuneOncia Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden
ACTI
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
United States of America
ACTU
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden
ACUC
Acurx Pharmaceuticals, Inc. Logo
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America
ACXP
Adagene Inc. Logo
Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.
United States of America
ADAG
Adaptimmune Therapeutics PLC Logo
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea
179530
ADC Therapeutics SA Logo
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America
ADCT
ADIAL PHARMACEUTICALS, INC. Logo
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Developing off-the-shelf gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET

Talk to a Data Expert

Have a question? We'll get back to you promptly.